Literature DB >> 27452455

Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.

David W Hawman1, Julie M Fox2, Alison W Ashbrook3, Nicholas A May1, Kristin M S Schroeder1, Raul M Torres1, James E Crowe4, Terence S Dermody5, Michael S Diamond6, Thomas E Morrison7.   

Abstract

Chikungunya virus (CHIKV) and related alphaviruses cause epidemics of acute and chronic musculoskeletal disease. To investigate the mechanisms underlying the failure of immune clearance of CHIKV, we studied mice infected with an attenuated CHIKV strain (181/25) and the pathogenic parental strain (AF15561), which differ by five amino acids. Whereas AF15561 infection of wild-type mice results in viral persistence in joint tissues, 181/25 is cleared. In contrast, 181/25 infection of μMT mice lacking mature B cells results in viral persistence in joint tissues, suggesting that virus-specific antibody is required for clearance of infection. Mapping studies demonstrated that a highly conserved glycine at position 82 in the A domain of the E2 glycoprotein impedes clearance and neutralization of multiple CHIKV strains. Remarkably, murine and human antibodies targeting E2 domain B failed to neutralize pathogenic CHIKV strains efficiently. Our data suggest that pathogenic CHIKV strains evade E2 domain-B-neutralizing antibodies to establish persistence.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27452455      PMCID: PMC5003573          DOI: 10.1016/j.celrep.2016.06.076

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  45 in total

1.  Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population.

Authors:  Marco Vignuzzi; Jeffrey K Stone; Jamie J Arnold; Craig E Cameron; Raul Andino
Journal:  Nature       Date:  2005-12-04       Impact factor: 49.962

2.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Authors:  Scott A Smith; Laurie A Silva; Julie M Fox; Andrew I Flyak; Nurgun Kose; Gopal Sapparapu; Solomiia Khomandiak; Solomiia Khomadiak; Alison W Ashbrook; Kristen M Kahle; Rachel H Fong; Sherri Swayne; Benjamin J Doranz; Charles E McGee; Mark T Heise; Pankaj Pal; James D Brien; S Kyle Austin; Michael S Diamond; Terence S Dermody; James E Crowe
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

Review 3.  Chikungunya: Evolutionary history and recent epidemic spread.

Authors:  Scott C Weaver; Naomi L Forrester
Journal:  Antiviral Res       Date:  2015-05-12       Impact factor: 5.970

Review 4.  Chikungunya fever: an epidemiological review of a re-emerging infectious disease.

Authors:  J Erin Staples; Robert F Breiman; Ann M Powers
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

5.  Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission.

Authors:  Jason Porta; Vidya Mangala Prasad; Cheng-I Wang; Wataru Akahata; Lisa F P Ng; Michael G Rossmann
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

6.  Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.

Authors:  David W Hawman; Kristina A Stoermer; Stephanie A Montgomery; Pankaj Pal; Lauren Oko; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

7.  Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.

Authors:  Chia Yin Lee; Yiu-Wing Kam; Jan Fric; Benoit Malleret; Esther G L Koh; Celine Prakash; Wen Huang; Wendy W L Lee; Cui Lin; Raymond T P Lin; Laurent Renia; Cheng-I Wang; Lisa F P Ng; Lucile Warter
Journal:  PLoS Pathog       Date:  2011-12-01       Impact factor: 6.823

8.  Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses.

Authors:  James Weger-Lucarelli; Matthew T Aliota; Attapon Kamlangdee; Jorge E Osorio
Journal:  PLoS Negl Trop Dis       Date:  2015-10-16

9.  Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period.

Authors:  Daouda Sissoko; Denis Malvy; Khaled Ezzedine; Philippe Renault; Frederic Moscetti; Martine Ledrans; Vincent Pierre
Journal:  PLoS Negl Trop Dis       Date:  2009-03-10

10.  Human muscle satellite cells as targets of Chikungunya virus infection.

Authors:  Simona Ozden; Michel Huerre; Jean-Pierre Riviere; Lark L Coffey; Philippe V Afonso; Vincent Mouly; Jean de Monredon; Jean-Christophe Roger; Mohamed El Amrani; Jean-Luc Yvin; Marie-Christine Jaffar; Marie-Pascale Frenkiel; Marion Sourisseau; Olivier Schwartz; Gillian Butler-Browne; Philippe Desprès; Antoine Gessain; Pierre-Emmanuel Ceccaldi
Journal:  PLoS One       Date:  2007-06-13       Impact factor: 3.240

View more
  32 in total

1.  Respiratory Enterovirus (like Parainfluenza Virus) Can Cause Chronic Lung Disease if Protection by Airway Epithelial STAT1 Is Lost.

Authors:  Yong Zhang; Dailing Mao; Shamus P Keeler; Xinyu Wang; Kangyun Wu; Benjamin J Gerovac; Laurie L Shornick; Eugene V Agapov; Michael J Holtzman
Journal:  J Immunol       Date:  2019-02-25       Impact factor: 5.422

2.  The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates.

Authors:  Natalie A Prow; Liang Liu; Mary K McCarthy; Kevin Walters; Raj Kalkeri; Jillian Geiger; Fusataka Koide; Tamara H Cooper; Preethi Eldi; Eri Nakayama; Kerrilyn R Diener; Paul M Howley; John D Hayball; Thomas E Morrison; Andreas Suhrbier
Journal:  NPJ Vaccines       Date:  2020-06-02       Impact factor: 7.344

3.  A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.

Authors:  Nurgun Kose; Julie M Fox; Gopal Sapparapu; Robin Bombardi; Rashika N Tennekoon; A Dharshan de Silva; Sayda M Elbashir; Matthew A Theisen; Elisabeth Humphris-Narayanan; Giuseppe Ciaramella; Sunny Himansu; Michael S Diamond; James E Crowe
Journal:  Sci Immunol       Date:  2019-05-17

Review 4.  Persistent RNA virus infections: do PAMPS drive chronic disease?

Authors:  Mary K McCarthy; Thomas E Morrison
Journal:  Curr Opin Virol       Date:  2017-02-17       Impact factor: 7.090

5.  Chikungunya Virus Evades Antiviral CD8+ T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues.

Authors:  Bennett J Davenport; Christopher Bullock; Mary K McCarthy; David W Hawman; Kenneth M Murphy; Ross M Kedl; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 6.  Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Authors:  Laurie A Silva; Terence S Dermody
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

7.  TF protein of Sindbis virus antagonizes host type I interferon responses in a palmitoylation-dependent manner.

Authors:  K J Rogers; S Jones-Burrage; W Maury; S Mukhopadhyay
Journal:  Virology       Date:  2020-01-07       Impact factor: 3.616

Review 8.  Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.

Authors:  Julie M Fox; Michael S Diamond
Journal:  J Immunol       Date:  2016-12-01       Impact factor: 5.422

9.  Mutations in the E2 Glycoprotein and the 3' Untranslated Region Enhance Chikungunya Virus Virulence in Mice.

Authors:  David W Hawman; Kathryn S Carpentier; Julie M Fox; Nicholas A May; Wes Sanders; Stephanie A Montgomery; Nathaniel J Moorman; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

10.  Chikungunya virus impairs draining lymph node function by inhibiting HEV-mediated lymphocyte recruitment.

Authors:  Mary K McCarthy; Bennett J Davenport; Glennys V Reynoso; Erin D Lucas; Nicholas A May; Susan A Elmore; Beth A Tamburini; Heather D Hickman; Thomas E Morrison
Journal:  JCI Insight       Date:  2018-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.